ANNOVIS BIO INC. DL-,0001

Annovis Bio has once again satisfied the NYSE's ongoing listing requirements after the company was placed under review in March 2025 for low market capitalization and shareholders’ equity. The NYSE accepted the compliance plan in June 2025, and Annovis cured the deficiency within 12 months; current market capitalization is $94.87 million. The common stock (ticker ANVS) posted a weekly performance of +15% but remains down 55% over six months; analyst price targets on InvestingPro range from $8 to $17. The company emphasizes continuation of its clinical programs and expects topline data from a phase 3 Alzheimer’s trial as well as potential regulatory filings. » More on de.investing.com

Annovis Bio reports that the drug buntanetap demonstrated statistically significant, dose‑dependent cognitive improvements (ADAS‑Cog11) over 12 weeks in a randomized, double‑blind phase‑2/3 trial in pTau217‑positive patients with mild Alzheimer’s disease. Buntanetap was safe and well tolerated across all stages and doses, including in ApoE4 carriers, and reduced multiple neurotoxic proteins as well as inflammation and neurodegeneration markers. The results were published in Nature NPJ Dementia; a registration‑enabling phase‑3 study for early stages is underway with about 80% enrollment. Despite the data, the stock is down 45% year‑to‑date; the company has a market capitalization of roughly USD 65 million. » More on de.investing.com

Annovis Bio has completed a capital increase and raised roughly $10 million gross, which the company says will secure liquidity through the second quarter of 2027. The funds are intended primarily to support operations and the approval‑relevant phase‑3 study of Buntanetap in Alzheimer’s disease; 75% of participants have already been recruited. A six‑month analysis of symptomatic data is expected in Q1 2027, and the FDA has agreed that safety data from earlier studies can be included in the regulatory submission. » More on de.investing.com